Clearside Biomedical 报告强劲的收益，主要眼部治疗产品的股票增加。 Clearside Biomedical reports strong earnings, boosting stock with key eye treatment products.

一家以眼科治疗为重点的生物制药公司 -- -- Clearside生物医学公司 -- -- 最近报告说,其季度收入和收入比预期的要好。 Clearside Biomedical, a biopharmaceutical company focused on eye treatments, recently reported better-than-expected quarterly earnings and revenue. 该公司的股票目前被评为“机动购买”,分析家预测价格目标会更高。 The company's stock is currently rated a "Moderate Buy" with analysts predicting a higher price target. 克莱尔赛德的主要产品XIPERE治疗紫外线斑点, 公司还在开发CLS-AX治疗湿与年龄相关的斑点退化, 目前正在临床试验中. Clearside's main product, XIPERE, treats uveitis macular edema, and it is also developing CLS-AX for wet age-related macular degeneration, which is in clinical trials.